New research from Washington State University in collaboration with five other institutions suggests that automated insulin ...

Automated insulin delivery systems are safe, effective, and well-received by older adults with type 1 diabetes, challenging ...

Sales Beat, Unexpected Profit. During the three months ended Dec. 31, Tandem Diabetes brought in $252.4 million in adjusted ...

"The risk of diabetic ketoacidosis linked to continuous subcutaneous insulin infusion in type 1 diabetes has significantly ...

Rhys Evans has been cycle touring with Type 1 diabetes for many years, but limited the distance. Following a tour across ...

New research suggests that automated insulin delivery (AID) systems are safe and effective for use by older adults with type 1 diabetes. The findings counter common assumptions that older adults would ...

Adults with type 1 diabetes who initiated treatment with a bionic pancreas at a primary care site experienced similar glycemic benefits as those starting the device through an endocrinologist, ...

An early-morning rise in blood sugar is common in people with diabetes. Find out more about why it happens and how to prevent ...

Why understanding the differences between Type 1 and Type 2 diabetes is essential for better health management and effective ...

Embecta's compelling ~44% free cash flow yield offers a strong risk-reward despite headwinds from new insulin technologies ...

Tandem Diabetes Care, Inc. reported strong Q4 2024 earnings, but shares declined 30%. Click for my TNDM stock update in light ...

Bernstein downgraded Tandem Diabetes (TNDM) to Market Perform from Outperform with a price target of $25, down from $35. The firm notes Tandem ...